Congestive Heart Failure
Conditions
Keywords
Extracorporeal Shockwave Therapy, Heart Failure, Congestive Heart Failure, Non-invasive, Device Trial, NYHA (New York Heart Association), Ischemic cardiomyopathy, Ischemia, Myocardial contractility
Brief summary
Evaluation of non-invasive treatment modality, using low-intensity extracorporeal shockwaves for treatment of subjects diagnosed with Congestive Heart Failure, with ischemic etiology.
Interventions
DEVICECardiospec
Non-invasive, low-intensity extracoporeal shockwaves at energy density of 0.99 mJ/mm2. 9 treatment sessions, 20 minutes each, over a period of 9 weeks (3 sessions on weeks 1, 5 and 9).
Sponsors
Tel-Aviv Sourasky Medical Center
Medispec
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patient is male or female 18 years or older. 2. Patient is diagnosed with a Heart Failure with ischemic etiology. Diagnosis is based on medical history, complete physical evaluation, and echocardiography. 3. Patient has documented myocardial segments with impaired contractility. Diagnosis is based on Rest Echo. 4. Patient is diagnosed with no more than 50% of segments akinetic or dyskinetic Diagnosis is based on echocardiography. 5. Patient is classified as NYHA II to IV. 6. Patient should be on a stable dosage of medication for at least 6 weeks prior to enrollment. 7. Patients Ejection Fraction \< 50%. 8. Patient is stable and without clinical events for \> 3 months. 9. Patient has signed an informed consent form. 10. Patient's condition should be stable and should have a life expectancy of \>12 months. 11. Patient's current and past medical condition and status will be assessed using previous medical history, physical evaluation, and the physicians (principle investigator's)medical opinion.
Exclusion criteria
1. Patient with intraventricular thrombus. 2. Severe COPD (patients with an FEV1 less than .8 liters). 3. Patient has chronic lung disease including emphysema and pulmonary fibrosis. 4. Patient has active endocarditis, myocarditis or pericarditis. 5. Patient is simultaneously participating in another device or drug study, or has participated in any clinical trial involving an experimental device or drug, including other drugs or devices enhancing cardiac neovascularization or any ESWT machine for neovascularization of a competitor company within 3 months of entry into the study. 6. Patients who are unwilling or unable to cooperate with study procedure. 7. Patients who are unwilling to quit smoking during the study procedure (including screening phase). 8. Patients who are diagnosed with severe valvular disease (regurgitation or stenosis). 9. Patient is pregnant. 10. Patient with a malignancy in the area of treatment without complete remission within 5 years(lungs, thorax, ribs).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The change in the number of myocardial segments that improve their contractility(at rest and at stress)at 6 months post baseline evaluations, evaluated by echocardiography. | 6 months | An echo examination shall be used to evaluate myocardial contractility post treatments. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 6 Minutes Walk Test (6MWT) | 6 months | Evaluation of 6MWT time from baseline to 6 months post baseline. |
Countries
Israel
Outcome results
None listed